Overview


According to FutureWise analysis the market for cancer diagnostics in 2023 is US$ 18.7 billion, and is expected to reach US$ over 30 billion by 2031 at a CAGR of 7.7%.

Cancer is a group of diseases defined by spread of abnormal cells and uncontrolled growth in the body. Early detection of cancer is critical for successful treatment and management of the disease. The goal of cancer diagnostics is to detect cancer early, determine its stage and type, and guide treatment decisions. The process of determining the existence and characteristics of the cancerous cells is known as cancer diagnostics. Imaging tests, biopsies, blood tests, and other laboratory studies are a few methods and steps used to detect and examine cancer cells. Cancer diagnostics aims to pinpoint the type, location, stage, and severity of the disease in addition to figuring out the best course of action. Successful cancer therapy and disease management depend on early detection and an accurate diagnosis.

Imaging tests, such as, CT scans, X-rays, PET, and MRI scans, are commonly used in cancer diagnostics to create images of the internal structures of the body. These tests can detect tumors and assess the extent of the disease, as well as monitor the effectiveness of treatment. Laboratory tests are also important in cancer diagnostics and are used to detect substances or markers in the blood or other bodily fluids that may be associated with cancer. Common laboratory tests used in cancer diagnosis include complete blood count, tumor markers, and biopsies. Biopsies are a key part of cancer diagnostics, and they involve the removal of a small sample of tissue from a suspicious area in the body for examination under a microscope. Different types of biopsies may be used, including core needle biopsy, surgical biopsy and fine-needle aspiration biopsy. Biopsies can help to confirm the diagnosis of cancer and determine its type.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Cancer Diagnostics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Cancer Diagnostics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • GE Healthcare
  • Abbott Laboratories
  • Hologic Inc.
  • Agilent Technologies Inc.
  • Roche Diagnostics
  • FUJIFILM Corporation
  • Danaher Corporation
  • DiaSorin S.P.A.
  • Myriad Genetics Inc.
  • Siemens Healthineers AG
  • BD
  • bioMérieux SA
  • Bio-Rad Laboratories
  • Cancer Diagnostics Inc.
  • Vela Diagnostics
  • AMOY Diagnostics CO. LTD.
  • Quidel Corporation
  • Bio SB
  • Biocartis NV
  • Exact Science

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Cancer Diagnostics Market:

Siemens Healthineers launched Magnetom Free in November 2021. It is a low-cost whole-body MRI scanner that intends to make magnetic resonance imaging accessible on a worldwide scale.

The European Commission authorised the use of the PD-L1 IHC 22C3 pharmDx test for triple-negative breast cancer in October 2021. 

The accuracy and speed of cancer diagnostics have significantly increased because of technological advancements, allowing earlier tumour diagnosis and more accurate tumour characterisation. The capacity to identify and describe cancer cells has significantly increased because of developments in imaging technologies like CT scans, MRIs, and PET scans as well as molecular diagnostic techniques like PCR, Next-Generation Sequencing, and liquid biopsy. A better analysis and interpretation of complicated data sets has also been made possible by the development of artificial intelligence and machine learning algorithms, increasing the precision and effectiveness of cancer detection. According to the World Health Organization, there were 10.3 million cancer-related deaths in 2020. Although early identification may greatly improve patient outcomes and survival rates, the rising frequency of cancer is driving need for improved diagnostic technologies.

However, there may be a considerable obstacle to the adoption and widespread use of these techniques due to the high cost of cancer diagnostics as well as regulatory and reimbursement issues. Yet, it is anticipated that the industry will continue to innovate and expand as a result of the increased need for precise, effective, and personalised cancer diagnoses.

By Product

  •  Consumables 
    •  Antibodies
    •  Kits & Reagents
    •  Probes
    •  Other Consumables 
  • Instruments
    •   Pathology-based Instruments
      •     Slide Staining Systems
      •     Tissue Processing Systems
      •     Cell Processors
      •     PCR Instruments
      •     NGS Instruments
      •     Microarrays
      •     Other Pathology-based Instruments
    •   Imaging Technologies Instruments
      •     CT Systems
      •     Ultrasound Systems
      •     MRI Systems
      •     Mammography Systems
      •     Nuclear Imaging Technologies Systems
      •  Biopsy Instruments 

By Technology 

  • IVD Testing
    •   Polymerase Chain Reaction (PCR)
    •   In Situ Hybridization (ISH)
    •   Immunohistochemistry (IHC)
    •   Next-generation Sequencing (NGS)
    •   Microarrays
    •    Flow Cytometry
    •   Immunoassays
    •   Other IVD Testing Technologies
  • Imaging Technologies 
    •   Magnetic Resonance Imaging Technologies (MRI)
    •   Computed Tomography (CT)
    •   Positron Emission Tomography (PET)
    •   Mammography
    •   Ultrasound
  • Biopsies

By Application 

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Melanoma
  • Other Cancers

By End User

  • Hospitals
  • Diagnostic Laboratories

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  •  Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  •  To provide with an exhaustive analysis on the Cancer Diagnostics Market By Product, By Technology, By Application, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  •  To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  •  To record and evaluate competitive landscape mapping- Technology launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Cancer Diagnostics Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Cancer Diagnostics Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Cancer Diagnostics Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Cancer Diagnostics Market, By Product Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Consumables
         1.1. Antibodies
         1.2. Kits and Reagents
         1.3. Probes
         1.4. Other Consumables
        2. Instruments
         2.1. Pathology-based Instruments
          2.1.1. Slide Staining Systems
          2.1.2. Tissue Processing Systems
          2.1.3. Cell Processors
          2.1.4. PCR Instruments
          2.1.5. NGS Instruments
          2.1.6. Microarrays
          2.1.7. Other Pathology-based Instruments
         2.2. Imaging Technologies Instruments
          2.2.1. CT Systems
          2.2.2. Ultrasound Systems
          2.2.3. MRI Systems
          2.2.4. Mammography Systems
          2.2.5. Nuclear Imaging Technologies Systems
        3. Biopsy Instruments

  • 8.   Cancer Diagnostics Market, By Technology Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. IVD Testing
         1.1. Polymerase Chain Reaction (PCR)
         1.2. In Situ Hybridization (ISH)
         1.3. Immunohistochemistry (IHC)
         1.4. Next-generation Sequencing (NGS)
         1.5. Microarrays
         1.6. Flow Cytometry
         1.7. Immunoassays
         1.8. Other IVD Testing Technologies
        2. Imaging Technologies
         2.1. Magnetic Resonance Imaging Technologies (MRI)
         2.2. Computed Tomography (CT)
         2.3. Positron Emission Tomography (PET)
         2.4. Mammography
         2.5. Ultrasound
        3. Biopsies

  • 9.   Cancer Diagnostics Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Breast Cancer
        2. Lung Cancer
        3. Colorectal Cancer
        4. Melanoma
        5. Other Cancers

  • 10.   Cancer Diagnostics Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Diagnostic Laboratories

  • 11.   North America Cancer Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Cancer Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Cancer Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Cancer Diagnostics Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. GE Healthcare
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Abbott Laboratories
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Hologic Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Agilent Technologies Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Roche Diagnostics
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. FUJIFILM Corporation
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Danaher Corporation
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. DiaSorin S.P.A.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Myriad Genetics Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Siemens Healthineers AG
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. BD
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. bioMérieux SA
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Bio-Rad Laboratories
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Cancer Diagnostics Inc.
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Vela Diagnostics
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. AMOY Diagnostics CO. LTD.
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. Quidel Corporation
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Bio SB
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. Biocartis NV
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Exact Science
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients